60 Degrees Pharmaceuticals Inc. announced the detection of Babesia infection in 24 percent of patients presenting with chronic fatigue, according to a peer-reviewed study conducted by researchers at North Carolina State University and published in Pathogens. The findings support the theory that Babesia infection may prolong recovery times in patients with chronic fatigue. The company also highlighted the ongoing B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating the efficacy and safety of the ARAKODA® (tafenoquine) regimen over 90 days for the resolution of severe fatigue in patients with chronic babesiosis. Results from the B-Free Study have not yet been presented, and the study is currently enrolling participants at the Icahn School of Medicine at Mount Sinai in New York. Tafenoquine is currently approved for malaria prophylaxis in the United States but is not approved for the treatment or prevention of babesiosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617405-en) on December 29, 2025, and is solely responsible for the information contained therein.